08:43 AM EDT, 09/17/2025 (MT Newswires) -- Elicio Therapeutics ( ELTX ) said Wednesday that immunogenicity testing data showed that about 99% of evaluable patients who were administered investigational cancer vaccine ELI-002 7P in an ongoing phase 2 trial generated "strong" T-cell responses, with an average increase of 145.3 times over baseline responses.

The results, which showed mKRAS-specific T-cell responses in 89 out of 90 patients, were "consistent" with observations from previous phase 1 trials of ELI-002, Elicio Chief Executive Robert Connelly said.

Connelly also said the data "set the stage for the final disease-free survival analysis," anticipated to take place in Q4.

Shares of the company were up 5.9% in recent premarket activity.